Systematic review of the efficacy, effectiveness and safety of MF59 ® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.

Autor: O Murchu E; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Health Policy & Management, School of Medicine, Trinity College Dublin, Dublin, Ireland., Comber L; Health Information and Quality Authority (HIQA), Dublin, Ireland., Jordan K; Health Information and Quality Authority (HIQA), Dublin, Ireland., Hawkshaw S; Health Information and Quality Authority (HIQA), Dublin, Ireland., Marshall L; Health Information and Quality Authority (HIQA), Dublin, Ireland., O'Neill M; Health Information and Quality Authority (HIQA), Dublin, Ireland., Ryan M; Health Information and Quality Authority (HIQA), Dublin, Ireland.; Department of Pharmacology & Therapeutics, Trinity College Dublin, Trinity Health Sciences, Dublin, Ireland., Teljeur C; Health Information and Quality Authority (HIQA), Dublin, Ireland., Carnahan A; Public Health Agency of Sweden, Solna, Sweden., Pérez JJ; General Directorate of Public Health and Addictions, IMIB-Arrixaca. Murcia University, Region of Murcia, Spain., Robertson AH; Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway., Johansen K; European Centre for Disease Prevention and Control, Solna, Sweden., Jonge J; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands., Krause T; Statens Serum Institut, Copenhagen, Denmark., Nicolay N; European Centre for Disease Prevention and Control, Solna, Sweden., Nohynek H; Finnish Institute for Health and Welfare, Helsinki, Finland., Pavlopoulou I; Pediatric Research Laboratory, School of Health Sciences, Faculty of Nursing National and Kapodistrian University of Athens, Athens, Greece.; National Advisory Committee on Immunisation, Hellenic Ministry of Health, Athens, Greece., Pebody R; Institute of Epidemiology & Health, University College London, London, UK., Penttinen P; European Centre for Disease Prevention and Control, Solna, Sweden., Soler-Soneira M; Vigilancia de Enfermedades Prevenibles por Vacunación, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, Madrid, Spain., Wichmann O; Immunization Unit, Robert Koch-Institute, Berlin, Germany., Harrington P; Health Information and Quality Authority (HIQA), Dublin, Ireland.
Jazyk: angličtina
Zdroj: Reviews in medical virology [Rev Med Virol] 2023 May; Vol. 33 (3), pp. e2329. Date of Electronic Publication: 2022 Feb 10.
DOI: 10.1002/rmv.2329
Abstrakt: The most effective means of preventing seasonal influenza is through vaccination. In this systematic review, we investigated the efficacy, effectiveness and safety of MF59 ® adjuvanted trivalent and quadrivalent influenza vaccines to prevent laboratory-confirmed influenza. A systematic literature search was conducted in electronic databases and grey literature sources up to 7 February 2020. Randomised controlled trials and non-randomised studies of interventions (NRSIs) were eligible for inclusion. The search returned 28,846 records, of which 48 studies on MF59 ® adjuvanted vaccines met our inclusion criteria. No efficacy trials were identified. In terms of vaccine effectiveness (VE), MF59 ® adjuvanted trivalent influenza vaccines were effective in preventing laboratory-confirmed influenza in older adults (aged ≥65 years) compared with no vaccination (VE = 45%, 95% confidence interval (CI) 23%-61%, 5 NRSIs across 3 influenza seasons). By subtype, significant effect was found for influenza A(H1N1) (VE = 61%, 95% CI 44%-73%) and B (VE = 29%, 95% CI 5%-46%), but not for A(H3N2). In terms of relative VE, there was no significant difference comparing MF59 ® adjuvanted trivalent vaccines with either non-adjuvanted trivalent or quadrivalent vaccines. Compared with traditional trivalent influenza vaccines, MF59 ® adjuvanted trivalent influenza vaccines were associated with a greater number of local adverse events (RR = 1.90, 95% CI 1.50-2.39) and systemic reactions (RR = 1.18, 95% CI 1.02-1.38). In conclusion, MF59 ® adjuvanted trivalent influenza vaccines were found to be more effective than 'no vaccination'. Based on limited data, there was no significant difference comparing the effectiveness of MF59 ® adjuvanted vaccines with their non-adjuvanted counterparts.
(© 2022 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: